Department of Pediatrics, Sections of Allergy and Immunology,
Section of Infectious Disease and Antimicrobial Stewardship, Children's Hospital Colorado, Aurora, Colorado; and.
Hosp Pediatr. 2021 May;11(5):427-434. doi: 10.1542/hpeds.2020-001636. Epub 2021 Apr 13.
Penicillin allergy is reported in up to 10% of the general population; however, >90% of patients reporting an allergy are tolerant. Patients labeled as penicillin allergic have longer hospital stays, increased exposure to suboptimal antibiotics, and an increased risk of methicillin-resistant and . The primary aim with our quality improvement initiative was to increase penicillin allergy delabeling to at least 10% among all hospitalized pediatric patients reporting a penicillin allergy with efforts directed toward patients determined to be low risk for true allergic reaction.
Our quality improvement project included several interventions: the development of a multidisciplinary clinical care pathway to identify eligible patients, workflow optimization to support delabeling, an educational intervention, and participation in our institution's quality improvement incentive program. Our interventions were targeted to facilitate appropriate delabeling by the primary hospital medicine team. Statistical process control charts were used to assess the impact of this intervention pre- and postpathway implementation.
After implementation of the clinical pathway, the percentage of patients admitted to hospital medicine delabeled of their penicillin allergy by discharge increased to 11.7%. More than one-half of those delabeled (51.2%) received a penicillin-based antimicrobial at time of discharge. There have been no adverse events or allergic reactions requiring emergency medication administration since pathway implementation.
Our quality improvement initiative successfully increased the rate of penicillin allergy delabeling among low-risk hospitalized pediatric patients, allowing for increased use of optimal antibiotics.
青霉素过敏在普通人群中的报告率高达 10%;然而,>90%报告过敏的患者是耐受的。被标记为青霉素过敏的患者住院时间更长,接触不理想抗生素的风险增加,并且耐甲氧西林金黄色葡萄球菌和 的风险增加。我们质量改进倡议的主要目标是将所有报告青霉素过敏的住院儿科患者中至少 10%的青霉素过敏标记去除,努力针对被确定为真正过敏反应风险较低的患者。
我们的质量改进项目包括几项干预措施:制定多学科临床护理路径,以确定合格患者,优化工作流程以支持标记去除,教育干预以及参与我们机构的质量改进激励计划。我们的干预措施旨在促进主要医院医学团队进行适当的标记去除。使用统计过程控制图评估该干预措施在实施前和实施后的影响。
在实施临床路径后,由医院医学科在出院时去除青霉素过敏标记的患者比例增加到 11.7%。超过一半(51.2%)去除标记的患者在出院时接受了基于青霉素的抗菌药物。自实施路径以来,没有发生不良事件或需要紧急药物治疗的过敏反应。
我们的质量改进倡议成功地提高了低风险住院儿科患者中去除青霉素过敏标记的比率,从而增加了最佳抗生素的使用。